How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/prevention-of-cmv-disease-after-organ-transplant.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prevention of CMV Disease After Organ Transplant — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of CMV Disease After Organ Transplant (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of CMV Disease After Organ Transplant, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zinecard	DEXRAZOXANE	Pfizer	Cytoprotective Agent	DNA topoisomerase 2-alpha	1995-01-01
Cytovene	GANCICLOVIR	Roche Palo	Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor	Metabotropic glutamate receptor 1	1989-01-01
Cytotec	misoprostol	Generic (originally Searle/Pfizer)	Prostaglandin E1 analog	Prostaglandin E2 receptor EP2 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin E2 receptor EP4 subtype	1988-12-27
Zinecard	Zinecard	M.D. Anderson Cancer Center		DNA topoisomerase 2-beta, DNA topoisomerase 2-alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Prevention of CMV Disease After Organ Transplant
Generic (originally Searle/Pfizer) · 1 drug in Prevention of CMV Disease After Organ Transplant
M.D. Anderson Cancer Center · 1 drug in Prevention of CMV Disease After Organ Transplant
Roche Palo · 1 drug in Prevention of CMV Disease After Organ Transplant

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of CMV Disease After Organ Transplant:

Cite this brief

Drug Landscape (2026). Prevention of CMV Disease After Organ Transplant — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-cmv-disease-after-organ-transplant. Accessed 2026-06-10.

Prevention of CMV Disease After Organ Transplant full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing